KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $837.2 million.

  • Halozyme Therapeutics' Total Current Liabilities rose 66940.5% to $837.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $837.2 million, marking a year-over-year increase of 66940.5%. This contributed to the annual value of $139.1 million for FY2024, which is 2365.1% up from last year.
  • Halozyme Therapeutics' Total Current Liabilities amounted to $837.2 million in Q3 2025, which was up 66940.5% from $134.3 million recorded in Q2 2025.
  • Halozyme Therapeutics' Total Current Liabilities' 5-year high stood at $837.2 million during Q3 2025, with a 5-year trough of $91.9 million in Q1 2023.
  • For the 5-year period, Halozyme Therapeutics' Total Current Liabilities averaged around $161.8 million, with its median value being $116.4 million (2023).
  • In the last 5 years, Halozyme Therapeutics' Total Current Liabilities crashed by 7219.95% in 2021 and then skyrocketed by 66940.5% in 2025.
  • Over the past 5 years, Halozyme Therapeutics' Total Current Liabilities (Quarter) stood at $117.1 million in 2021, then grew by 11.65% to $130.8 million in 2022, then decreased by 13.99% to $112.5 million in 2023, then rose by 23.65% to $139.1 million in 2024, then skyrocketed by 501.89% to $837.2 million in 2025.
  • Its last three reported values are $837.2 million in Q3 2025, $134.3 million for Q2 2025, and $150.4 million during Q1 2025.